The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions

The consensus Immunoscore is a routine assay quantifying the adaptive immune response within the tumor microenvironment. It has a prognostic value that has been confirmed in a phase 3 clinical trial (NCCTG N0147) in stage III colon cancers. Moreover, results from another phase 3 randomized trial rev...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanzi, Anastasia, Sinicrope, F. A., Benson, A. B., Galon, Jérôme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466859/
https://www.ncbi.nlm.nih.gov/pubmed/32934890
http://dx.doi.org/10.1080/2162402X.2020.1796003
_version_ 1783577904905453568
author Lanzi, Anastasia
Sinicrope, F. A.
Benson, A. B.
Galon, Jérôme
author_facet Lanzi, Anastasia
Sinicrope, F. A.
Benson, A. B.
Galon, Jérôme
author_sort Lanzi, Anastasia
collection PubMed
description The consensus Immunoscore is a routine assay quantifying the adaptive immune response within the tumor microenvironment. It has a prognostic value that has been confirmed in a phase 3 clinical trial (NCCTG N0147) in stage III colon cancers. Moreover, results from another phase 3 randomized trial revealed the predictive value of Immunoscore for response to adjuvant chemotherapy duration. These results highlight the clinical utility of Immunoscore. In its latest edition, the World Health Organization classification of Digestive System Tumors introduced for the first time the immune response as an essential and desirable diagnostic criterion for colorectal cancer. Within the tumor microenvironment, the immune response provides an important estimate of the risk of recurrence and death in colon cancer. The international validation of the prognostic value of the consensus Immunoscore together with its prognostic value in the N0147 trial and its predictive utility for response to chemotherapy in stage III patients provide valuable information for patient management.
format Online
Article
Text
id pubmed-7466859
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-74668592020-09-14 The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions Lanzi, Anastasia Sinicrope, F. A. Benson, A. B. Galon, Jérôme Oncoimmunology Author's View The consensus Immunoscore is a routine assay quantifying the adaptive immune response within the tumor microenvironment. It has a prognostic value that has been confirmed in a phase 3 clinical trial (NCCTG N0147) in stage III colon cancers. Moreover, results from another phase 3 randomized trial revealed the predictive value of Immunoscore for response to adjuvant chemotherapy duration. These results highlight the clinical utility of Immunoscore. In its latest edition, the World Health Organization classification of Digestive System Tumors introduced for the first time the immune response as an essential and desirable diagnostic criterion for colorectal cancer. Within the tumor microenvironment, the immune response provides an important estimate of the risk of recurrence and death in colon cancer. The international validation of the prognostic value of the consensus Immunoscore together with its prognostic value in the N0147 trial and its predictive utility for response to chemotherapy in stage III patients provide valuable information for patient management. Taylor & Francis 2020-07-20 /pmc/articles/PMC7466859/ /pubmed/32934890 http://dx.doi.org/10.1080/2162402X.2020.1796003 Text en © 2020 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Author's View
Lanzi, Anastasia
Sinicrope, F. A.
Benson, A. B.
Galon, Jérôme
The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions
title The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions
title_full The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions
title_fullStr The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions
title_full_unstemmed The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions
title_short The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions
title_sort consensus immunoscore in phase 3 clinical trial (n0147) and impact on patient management decisions
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466859/
https://www.ncbi.nlm.nih.gov/pubmed/32934890
http://dx.doi.org/10.1080/2162402X.2020.1796003
work_keys_str_mv AT lanzianastasia theconsensusimmunoscoreinphase3clinicaltrialn0147andimpactonpatientmanagementdecisions
AT sinicropefa theconsensusimmunoscoreinphase3clinicaltrialn0147andimpactonpatientmanagementdecisions
AT bensonab theconsensusimmunoscoreinphase3clinicaltrialn0147andimpactonpatientmanagementdecisions
AT galonjerome theconsensusimmunoscoreinphase3clinicaltrialn0147andimpactonpatientmanagementdecisions
AT lanzianastasia consensusimmunoscoreinphase3clinicaltrialn0147andimpactonpatientmanagementdecisions
AT sinicropefa consensusimmunoscoreinphase3clinicaltrialn0147andimpactonpatientmanagementdecisions
AT bensonab consensusimmunoscoreinphase3clinicaltrialn0147andimpactonpatientmanagementdecisions
AT galonjerome consensusimmunoscoreinphase3clinicaltrialn0147andimpactonpatientmanagementdecisions

Ejemplares similares